Oncology

Benustin
Lyophilized powder for solution for infusions 25 mg 100 mg
Сytostatic antitumour alkylating agent. It is indicated for treatment of chronic lymphocytic leukaemia (Binet stage B or C), indolent non-Hodgkin's lymphomas, first-line treatment of multiple myeloma (Durie-Salmon stage II with progress or stage III) in combination with prednisone